Biopharmaceutical industry conducts clinical trials and product application issues and countermeasures in Shenzhen
10.3760/cma.j.cn113565-20240307-00069
- VernacularTitle:深圳市生物医药产业开展临床试验的问题及对策
- Author:
Yue ZHANG
1
;
Yangxiaohong XIE
1
;
Ping JI
1
;
Ping XIAO
1
Author Information
1. 深圳北京大学香港科技大学医学中心，深圳 518036
- Publication Type:Journal Article
- Keywords:
Biomedical industry;
Clinical trials;
Countermeasures
- From:
Chinese Journal of Medical Science Research Management
2025;38(4):347-352
- CountryChina
- Language:Chinese
-
Abstract:
Objective:The biomedical industry in Shenzhen is developing at an accelerating pace; however, bottlenecks exist in its collaboration with medical and health institutions in conducting clinical trials. This has resulted in enterprises and medical institutions being unable to effectively advance the development of trials.Methods:In response to this situation, the Shenzhen Municipal Government has conducted a series of surveys. Employing a mixed qualitative research design to grasp the current development status of the biopharmaceutical industry, it organized experts from relevant fields within pharmaceutical manufacturers and medical institutions across the city. These experts, from diverse perspectives, comprehensively reviewed and analyzed the current status and challenges of clinical trial implementation in Shenzhen, and proposed targeted countermeasures.Results:The outcomes include optimizing the layout of the biomedical industry, enhancing hospitals' capacity and motivation to undertake clinical trials, and refining the existing clinical trial system-all aimed at breaking through the existing challenges and difficulties.Conclusions:The development of biomedicine can drive progress in healthcare, improve patient diagnosis and treatment, and boost urban innovation. By addressing the bottlenecks in clinical trial collaboration and local product application, and breaking down existing barriers through joint efforts, we can promote industrial growth, elevate the professional competence and standards of healthcare institutions, and achieve mutual development and progress.
